Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

被引：2
|
作者：
Nitz, Ulrike [1 ,2 ]
Gluz, Oleg [1 ,2 ]
Kates, Ronald E. [1 ]
Hofmann, Daniel [1 ]
Kreipe, Hans H. [3 ]
Christgen, Matthias [3 ]
Shak, Steve [4 ]
Clemens, Michael [5 ]
Kraemer, Stefan
Aktas, Bahriye [6 ]
Kuemmel, Sherko [7 ]
Reimer, Toralf [8 ]
Kusche, Manfred [9 ]
Heyl, Volker [10 ]
Lorenz-Salehi, Fatemah [11 ]
Just, Marianne [12 ]
Liedtke, Cornelia [1 ,13 ]
Wuerstlein, Rachel [1 ,14 ]
Harbeck, Nadia [1 ,14 ]
机构：
[1] West German Study Grp, Dusseldorf, Germany
[2] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
[4] Genom Hlth Inc, Redwood City, CA USA
[5] Breast Ctr, Mutterhaus Borromaerinnen, Trier, Germany
[6] Univ Clin Essen, Women Clin, Essen, Germany
[7] Clin Essen Mitte, Women Clin, Essen, Germany
[8] Clin Suedstadt, Rostock, Germany
[9] Marien Hosp Aachen, Women Clin, Aachen, Germany
[10] Asklepios Paulinen Clin, Wiesbaden, Germany
[11] Dr Horst Schmidt Clin, Women Clin, Wiesbaden, Germany
[12] Oncol Practice, Bielefeld, Germany
[13] Univ Clin Schleswig Holstein, Kiel, Germany
[14] LMU, Univ Clin Grosshadern, Breast Ctr, Munich, Germany
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P4-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-11-01
引用
收藏
页数：2
相关论文
共 36 条
  • [21] Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.
    Degenhardt, Tom
    Kreipe, Hans Heinrich
    Gluz, Oleg
    Kates, Ronald E.
    Liedtke, Cornelia
    Kraemer, Stefan
    Clemens, Michael R.
    Nuding, Benno
    Reimer, Toralf
    Aktas, Bahriye
    Kummel, Sherko
    Just, Marianne
    Lorenz-Salehi, Fatemeh
    Uleer, Christoph
    Stefek, Andrea
    Heyl, Volker
    Wuerstlein, Rachel
    Nitz, Ulrike
    Harbeck, Nadia
    Christgen, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014)
    Nitz, U.
    Gluz, O.
    Huober, J.
    Kreipe, H. H.
    Kates, R. E.
    Hartmann, A.
    Erber, R.
    Moustafa, Z.
    Scholz, M.
    Lisboa, B.
    Mohrmann, S.
    Moebus, V.
    Augustin, D.
    Hoffmann, G.
    Weiss, E.
    Boehmer, S.
    Kreienberg, R.
    Du Bois, A.
    Sattler, D.
    Thomssen, C.
    Kiechle, M.
    Jaenicke, F.
    Wallwiener, D.
    Harbeck, N.
    Kuhn, W.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2899 - 2899
  • [23] Prospective comparison of uPA/PAI-1, Ki-67 based molecular classification, Recurrence Score and clinical-pathological characteristics in hormone-receptor (HR) positive primary breast cancer: Pilot phase of the randomized WSG PlanB trial
    Liedtke, C.
    Gluz, O.
    Kreipe, H.
    Degenhardt, T.
    Kates, R.
    Baehner, R.
    Clemens, M.
    Wuerstlein, R.
    Nitz, U.
    Harbeck, N.
    BREAST, 2011, 20 : S38 - S38
  • [24] Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer
    Nitz, U.
    Gluz, O.
    Zuna, I.
    Oberhoff, C.
    Reimer, T.
    Schumacher, C.
    Hackmann, J.
    Warm, M.
    Uleer, C.
    Runde, V.
    Duennebacke, J.
    Belzl, N.
    Augustin, D.
    Kates, R. E.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 75 - 80
  • [25] Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial
    Harbeck, Nadia
    Gluz, Oleg
    Kuemmel, Sherko
    Christgen, Matthias
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Darsow, Maren
    Krauss, Katja
    Nuding, Benno
    Thill, Marc
    Potenberg, Jochem
    Uleer, Christoph
    Warm, Mathias
    Fischer, Hans H.
    Malter, Wolfram
    Hauptmann, Michael
    Kates, Ronald
    Graeser, Monika
    Wuerstlein, Rachel
    Shak, Steve
    Baehner, Rick
    Kreipe, Hans
    Nitz, Ulrike
    CANCER RESEARCH, 2021, 81 (04)
  • [26] Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer
    Harbeck, Nadia
    Gluz, Oleg
    Clemens, Michael R.
    Malter, Wolfram
    Reimer, Toralf
    Nuding, Benno
    Aktas, Bahriye
    Stefek, Andrea
    Pollmanns, Anke
    Lorenz-Salehi, Fatemeh
    Uleer, Christoph
    Krabisch, Petra
    Kummel, Sherko
    Liedtke, Cornelia
    Shak, Steven
    Wuerstlein, Rachel
    Christgen, Matthias
    Kates, Ronald
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
    Nitz, Ulrike
    Gluz, Oleg
    Christgen, Matthias
    Kates, Ronald E.
    Clemens, Michael
    Malter, Wolfram
    Nuding, Benno
    Aktas, Bahriye
    Kuemmel, Sherko
    Reimer, Toralf
    Stefek, Andrea
    Lorenz-Salehi, Fatemeh
    Krabisch, Petra
    Just, Marianne
    Augustin, Doris
    Liedtke, Cornelia
    Chao, Calvin
    Shak, Steven
    Wuerstlein, Rachel
    Kreipe, Hans H.
    Harbeck, Nadia
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 573 - 583
  • [28] Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial
    Smith, Ian
    Robertson, John
    Kilburn, Lucy
    Wilcox, Maggie
    Evans, Abigail
    Holcombe, Chris
    Horgan, Kieran
    Kirwan, Cliona
    Mallon, Elizabeth
    Sibbering, Mark
    Skene, Anthony
    Vidya, Raghavan
    Cheang, Maggie
    Banerji, Jane
    Morden, James
    Sidhu, Kally
    Dodson, Andrew
    Bliss, Judith M.
    Dowsett, Mitch
    LANCET ONCOLOGY, 2020, 21 (11): : 1443 - 1454
  • [29] Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
    Goetz, M. P.
    Turner, N.
    Sasano, H.
    Arteaga, C.
    Chandarlapaty, S.
    Loi, S.
    Reis-Filho, J. S.
    Kreipe, H.
    Harbeck, N.
    Fasching, P.
    Rubenstein, C. S.
    Wijayawardana, S.
    Munoz, M.
    Litchfield, M.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2023, 34 : S278 - S279
  • [30] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
    Ulrike Nitz
    Oleg Gluz
    Matthias Christgen
    Ronald E. Kates
    Michael Clemens
    Wolfram Malter
    Benno Nuding
    Bahriye Aktas
    Sherko Kuemmel
    Toralf Reimer
    Andrea Stefek
    Fatemeh Lorenz-Salehi
    Petra Krabisch
    Marianne Just
    Doris Augustin
    Cornelia Liedtke
    Calvin Chao
    Steven Shak
    Rachel Wuerstlein
    Hans H. Kreipe
    Nadia Harbeck
    Breast Cancer Research and Treatment, 2017, 165 : 573 - 583
1234